Cyclohexanone-based ketamine metabolite with AMPA receptor-potentiating and rapid antidepressant activity
A hydroxylated norketamine metabolite identified as a principal mediator of ketamine’s rapid antidepressant effects, distinguished from the parent compound by the absence of NMDA receptor blockade at therapeutic concentrations, lack of dissociative and abuse-related properties, and a novel mechanism converging on AMPA receptor potentiation, BDNF-TrkB signaling, and mGlu2 receptor-dependent glutamatergic plasticity.
Abstract
Hydroxynorketamine (HNK) refers to a family of twelve stereoisomeric metabolites of the dissociative anesthetic and rapid-acting antidepressant ketamine, formed by cytochrome P450-mediated hydroxylation of the intermediate metabolite norketamine at the 4-, 5-, or 6-position of the cyclohexane ring. The (2R,6R)-hydroxynorketamine stereoisomer ((2R,6R)-HNK) has emerged as the compound of greatest pharmacological interest following the seminal 2016 report by Zanos et al. in Nature demonstrating that this metabolite is both necessary and sufficient for the antidepressant actions of ketamine in rodent models, while lacking the anesthetic, dissociative, psychotomimetic, and abuse-related properties of the parent compound. The molecular pharmacology of (2R,6R)-HNK is distinct from ketamine: at concentrations relevant to antidepressant activity, (2R,6R)-HNK does not produce meaningful inhibition of N-methyl-D-aspartate (NMDA) receptors, but instead potentiates alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated glutamatergic transmission through a presynaptic mechanism that increases glutamate release probability and enhances synaptic plasticity in hippocampal and prefrontal cortical circuits. Downstream consequences include activity-dependent release of brain-derived neurotrophic factor (BDNF), activation of tropomyosin receptor kinase B (TrkB) signaling, stimulation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway, and rapid synaptogenesis in the medial prefrontal cortex. Additional mechanistic contributions involve metabotropic glutamate receptor subtype 2 (mGlu2) receptor-dependent signaling and antagonism of alpha-7 nicotinic acetylcholine receptors controlling presynaptic function and neuroplasticity gene expression. Pharmacokinetically, (2R,6R)-HNK is formed in vivo from (R)-ketamine through sequential N-demethylation (predominantly CYP2B6 and CYP3A4) to (R)-norketamine and subsequent 6-hydroxylation (predominantly CYP2B6 and CYP2A6). The metabolite is brain-penetrant following peripheral administration, with rapid onset of central nervous system exposure. Phase 2 trials in treatment-resistant depression (NCT06511908) and Phase 1/2 trials in neuropathic pain (NCT05864053) and obsessive-compulsive disorder (NCT06575075) are currently enrolling. Preclinical evidence across multiple rodent models demonstrates antidepressant-like, anxiolytic, analgesic, and anti-inflammatory effects, with effect sizes comparable to or exceeding those of the parent ketamine in several paradigms and duration of action extending well beyond the plasma residence time, consistent with a synaptic plasticity-dependent rather than receptor occupancy-dependent mechanism. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.